Nature’s Way Acquires Enzymatic Therapy

[GhostModder]

Springville, UT-based Nature’s Way Holding Company, a subsidiary of Germany-based Dr. Willmar Schwabe Pharmaceuticals, has reached an agreement with North CastlePartners, LLC to acquire all outstanding shares of Enzymatic Therapy, Green Bay, WI, pending approval of other shareholders.

Schwabe Pharmaceuticals comprises six companies in Germany and more than 20 subsidiaries and joint ventures around the world. The initial focus of the deal will be to advance product development and bring more natural health solutions to market.

“We believe the complementary product portfolios and marketing know-how of Enzymatic Therapy and Nature’s Way will significantly strengthen our presence in the U.S. market, which is one of Schwabe’s strategic key markets for future growth,” said Dr. Dirk Reischig, chairman and CEO of Schwabe Pharmaceuticals.

Lincoln International, a mid-market investment bank that completed the transaction, acted as the exclusive financial advisor to Schwabe Pharmaceuticals and Nature’s Way. Lincoln worked directly with the Board of Directors and senior management teams of both companies.

“We look forward to leveraging the knowledge and expertise in our companies and to further enhance the significant business growth that both Nature’s Way and Enzymatic Therapy have enjoyed over the past several years,” said Rory Mahony, CEO of Nature’s Way. “We believe the dedication of the companies to the development of quality products will benefit our customers in many ways.”

Randy Rose, CEO of Enzymatic Therapy said, “The highly ethical approach to delivering true natural medicines that improve lives is a consistent core value for all three entities and we look forward to advancing the natural healthcare solutions for the benefit of all."

More...